A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Efavaleukin alfa (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Amgen
- 24 Oct 2019 Planned primary completion date changed from 3 Dec 2021 to 28 Jan 2020.
- 24 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Oct 2019 Planned End Date changed from 11 May 2022 to 9 Sep 2022.